Skip to main content
. 2014 Sep 17;2014:265840. doi: 10.1155/2014/265840

Figure 6.

Figure 6

Effect of lenalidomide on the expression of NK cell activating receptors. PBMCs from healthy donors and CLL patients were treated with 1 μM lenalidomide or DMSO for 7 days and the expression of NKG2D, DNAM-1, NKp30, NKp44, and NKp46 on NK cells (CD3CD56+) was analyzed by flow cytometry. The figure shows the compilation of the results obtained from patients (n = 4) and donors (n = 3) before and after lenalidomide treatment. The bars represent the mean and standard deviation of the MFI.